

HOUSE BILL NO. 690

INTRODUCED BY GLASER, BRANDEWIE

IN THE HOUSE

FEBRUARY 10, 1987 INTRODUCED AND REFERRED TO COMMITTEE
ON HUMAN SERVICES & AGING.

FEBRUARY 16, 1987 COMMITTEE RECOMMEND BILL
DO PASS AS AMENDED. REPORT ADOPTED.

FEBRUARY 17, 1987 PRINTING REPORT.

FEBRUARY 18, 1987 SECOND READING, DO PASS.

FEBRUARY 19, 1987 ENGROSSING REPORT.

 THIRD READING, PASSED.
 AYES, 92; NOES, 0.

 TRANSMITTED TO SENATE.

IN THE SENATE

FEBRUARY 21, 1987 INTRODUCED AND REFERRED TO COMMITTEE
ON PUBLIC HEALTH, WELFARE & SAFETY.

MARCH 25, 1987 COMMITTEE RECOMMEND BILL BE
CONCURRED IN. REPORT ADOPTED.

MARCH 28, 1987 SECOND READING, CONCURRED IN.

MARCH 30, 1987 THIRD READING, CONCURRED IN.
 AYES, 50; NOES, 0.

 RETURNED TO HOUSE.

IN THE HOUSE

MARCH 31, 1987 RECEIVED FROM SENATE.

 SENT TO ENROLLING.

1 House BILL NO. 690
2 INTRODUCED BY Mr. E. Blum B. Lewis
3

4 A BILL FOR AN ACT ENTITLED: "AN ACT AUTHORIZING THE
5 MANUFACTURE, SALE, POSSESSION, AND DISTRIBUTION OF
6 CALCIUM-EAP, HARNOSAL, AND PHOSETAMIN; AND PROVIDING AN
7 IMMEDIATE EFFECTIVE DATE."
8

9 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MONTANA:

10 Section 1. Purpose. The purpose of this act is to
11 provide for the continuation of medication initiated by a
12 physician for multiple sclerosis. This medication includes
13 the substances described in [this act] and has been found to
14 be effective in alleviating the symptoms of multiple
15 sclerosis.

16 Section 2. Definitions. In [this act], the following
17 definitions apply:

18 (1) "Calcium-EAP" means a calcium salt of the
19 monoester (2-ethylamine) of phosphoric acid.

20 (2) "Harnosal" means a compound of sulfamethizole and
21 sulfaethidole. A 500-milligram tablet contains 350
22 milligrams of sulfamethizole and 150 milligrams of
23 sulfaethidole.

24 (3) "Phosetamin" means a compound of potassium salt of
25 the monoester (2-ethylamine) of phosphoric acid, magnesium

1 salt of the monoester (2-ethylamine) of phosphoric acid, and
2 calcium salt of the monoester (2-ethylamine) of phosphoric
3 acid. A 350-milligram tablet contains 145.8 milligrams of
4 the potassium salt, 145.8 milligrams of the magnesium salt,
5 and 58.4 milligrams of the calcium salt.

6 Section 3. Authorization of medication. The
7 manufacture, sale, possession, and distribution of
8 calcium-EAP, harnosal, and phosetamin are lawful within this
9 state.

10 Section 4. Health care facility may not interfere. A
11 health care facility may not interfere with the
12 physician-patient relationship by restricting or forbidding
13 the use of calcium-EAP, harnosal, or phosetamin when
14 prescribed or administered by a physician.

15 Section 5. Health care facility immunity. No health
16 care facility or employee thereof may be held liable for the
17 administration of calcium-EAP, harnosal, or phosetamin to
18 any person.

19 Section 6. Physician not subject to disciplinary
20 action. A physician may not be disciplined by the board of
21 medical examiners for prescribing or administering
22 calcium-EAP, harnosal, or phosetamin to a patient under his
23 care in the treatment of any malignancy, disease, illness,
24 or physical condition.

25 Section 7. Medication not endorsed -- permitted as



-2- INTRODUCED BILL
HB 690

1 dietary supplement. [This act]:

2 (1) is not an endorsement of calcium-EAP, harnosal, or
3 phosetamin for the treatment of any malignancy, disease,
4 illness, or physical condition; and

5 (2) does not prohibit use of calcium-EAP, harnosal, or
6 phosetamin as a dietary supplement.

7 Section 8. Medication not required. [This act] does
8 not require:

9 (1) a physician to prescribe calcium-EAP, harnosal, or
10 phosetamin for any patient; or

11 (2) a physician, pharmacist, pharmacy, manufacturer,
12 or distributor to manufacture, sell, or distribute
13 calcium-EAP, harnosal, or phosetamin.

14 Section 9. Effective date. This act is effective on
15 passage and approval.

-End-

APPROVED BY COMM. ON
HUMAN SERVICES AND AGING

HOUSE BILL NO. 690

INTRODUCED BY GLASER, BRANDEWIE

A BILL FOR AN ACT ENTITLED: "AN ACT AUTHORIZING THE
MANUFACTURE, SALE, POSSESSION, AND DISTRIBUTION OF
CALCIUM-EAP, HARNOSAL, AND PHOSETAMIN; AND PROVIDING AN
IMMEDIATE EFFECTIVE DATE."

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MONTANA:

Section 1. Purpose. The purpose of this act is to
provide for the continuation of medication initiated by a
physician for multiple sclerosis. This medication includes
the substances described in [this act] and has been found to
be effective in alleviating the symptoms of multiple
sclerosis.

Section 2. Definitions. In [this act], the following
definitions apply:

(1) "Calcium-EAP" means a calcium salt of the
monoester (2-ethylamine) of phosphoric acid.

(2) "Harnosal" means a compound of sulfamethizole and
sulfaethidole. A 500-milligram tablet contains 350
milligrams of sulfamethizole and 150 milligrams of
sulfaethidole.

(3) "Phosetamin" means a compound of potassium salt of
the monoester (2-ethylamine) of phosphoric acid, magnesium


salt of the monoester (2-ethylamine) of phosphoric acid, and
calcium salt of the monoester (2-ethylamine) of phosphoric
acid. A 350-milligram tablet contains 145.8 milligrams of
the potassium salt, 145.8 milligrams of the magnesium salt,
and 58.4 milligrams of the calcium salt SALT.

Section 3. Authorization of medication. The
manufacture, sale, possession, and distribution of
calcium-EAP, harnosal, and phosetamin TO PROVIDE FOR THE
CONTINUATION OF MEDICATION INITIATED BY A PHYSICIAN FOR
MULTIPLE SCLEROSIS are lawful within this state.

Section 4. Health care facility may not interfere. A
health care facility may not interfere with the
physician-patient relationship by restricting or forbidding
the use of calcium-EAP, harnosal, or phosetamin when
prescribed or administered by a physician.

Section 5. Health care facility immunity. No health
care facility or employee thereof may be held liable for the
administration of calcium-EAP, harnosal, or phosetamin to
any person.

Section 6. Physician not subject to disciplinary
action. A physician may not be disciplined by the board of
medical examiners for prescribing or administering
calcium-EAP, harnosal, or phosetamin to a patient under his
care in the treatment of any malignancy, disease, illness,
or physical condition.



1 Section 7. Medication not endorsed -- permitted as
2 dietary supplement. [This act]:

3 (1) is not an endorsement of calcium-EAP, harnosal, or
4 phosetamin for the treatment of any malignancy, disease,
5 illness, or physical condition; and

6 (2) does not prohibit use of calcium-EAP, harnosal, or
7 phosetamin as a dietary supplement.

8 Section 8. Medication not required. [This act] does
9 not require:

10 (1) a physician to prescribe calcium-EAP, harnosal, or
11 phosetamin for any patient; or

12 (2) a physician, pharmacist, pharmacy, manufacturer,
13 or distributor to manufacture, sell, or distribute
14 calcium-EAP, harnosal, or phosetamin.

15 Section 9. Effective date. This act is effective on
16 passage and approval.

-End-

1 HOUSE BILL NO. 690

2 INTRODUCED BY GLASER, BRANDEWIE

3
4 A BILL FOR AN ACT ENTITLED: "AN ACT AUTHORIZING THE
5 MANUFACTURE, SALE, POSSESSION, AND DISTRIBUTION OF
6 CALCIUM-EAP, HARNOSAL, AND PHOSETAMIN; AND PROVIDING AN
7 IMMEDIATE EFFECTIVE DATE."
8

9 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MONTANA:

10 Section 1. Purpose. The purpose of this act is to
11 provide for the continuation of medication initiated by a
12 physician for multiple sclerosis. This medication includes
13 the substances described in [this act] and has been found to
14 be effective in alleviating the symptoms of multiple
15 sclerosis.

16 Section 2. Definitions. In [this act], the following
17 definitions apply:

18 (1) "Calcium-EAP" means a calcium salt of the
19 monoester (2-ethylamine) of phosphoric acid.

20 (2) "Harnosal" means a compound of sulfamethizole and
21 sulfaethidole. A 500-milligram tablet contains 350
22 milligrams of sulfamethizole and 150 milligrams of
23 sulfaethidole.

24 (3) "Phosetamin" means a compound of potassium salt of
25 the monoester (2-ethylamine) of phosphoric acid, magnesium

1 salt of the monoester (2-ethylamine) of phosphoric acid, and
2 calcium salt of the monoester (2-ethylamine) of phosphoric
3 acid. A 350-milligram tablet contains 145.8 milligrams of
4 the potassium salt, 145.8 milligrams of the magnesium salt,
5 and 58.4 milligrams of the calcium salt SALT.

6 Section 3. Authorization of medication. The
7 manufacture, sale, possession, and distribution of
8 calcium-EAP, harnosal, and phosetamin TO PROVIDE FOR THE
9 CONTINUATION OF MEDICATION INITIATED BY A PHYSICIAN FOR
10 MULTIPLE SCLEROSIS are lawful within this state.

11 Section 4. Health care facility may not interfere. A
12 health care facility may not interfere with the
13 physician-patient relationship by restricting or forbidding
14 the use of calcium-EAP, harnosal, or phosetamin when
15 prescribed or administered by a physician.

16 Section 5. Health care facility immunity. No health
17 care facility or employee thereof may be held liable for the
18 administration of calcium-EAP, harnosal, or phosetamin to
19 any person.

20 Section 6. Physician not subject to disciplinary
21 action. A physician may not be disciplined by the board of
22 medical examiners for prescribing or administering
23 calcium-EAP, harnosal, or phosetamin to a patient under his
24 care in the treatment of any malignancy, disease, illness,
25 or physical condition.

1 Section 7. Medication not endorsed -- permitted as
2 dietary supplement. [This act]:

3 (1) is not an endorsement of calcium-EAP, harnosal, or
4 phosetamin for the treatment of any malignancy, disease,
5 illness, or physical condition; and

6 (2) does not prohibit use of calcium-EAP, harnosal, or
7 phosetamin as a dietary supplement.

8 Section 8. Medication not required. [This act] does
9 not require:

10 (1) a physician to prescribe calcium-EAP, harnosal, or
11 phosetamin for any patient; or

12 (2) a physician, pharmacist, pharmacy, manufacturer,
13 or distributor to manufacture, sell, or distribute
14 calcium-EAP, harnosal, or phosetamin.

15 Section 9. Effective date. This act is effective on
16 passage and approval.

-End-

1 HOUSE BILL NO. 690

2 INTRODUCED BY GLASER, BRANDEWIE

3
4 A BILL FOR AN ACT ENTITLED: "AN ACT AUTHORIZING THE
5 MANUFACTURE, SALE, POSSESSION, AND DISTRIBUTION OF
6 CALCIUM-EAP, HARNOSAL, AND PHOSETAMIN; AND PROVIDING AN
7 IMMEDIATE EFFECTIVE DATE."

8
9 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MONTANA:

10 Section 1. Purpose. The purpose of this act is to
11 provide for the continuation of medication initiated by a
12 physician for multiple sclerosis. This medication includes
13 the substances described in [this act] and has been found to
14 be effective in alleviating the symptoms of multiple
15 sclerosis.

16 Section 2. Definitions. In [this act], the following
17 definitions apply:

18 (1) "Calcium-EAP" means a calcium salt of the
19 monoester (2-ethylamine) of phosphoric acid.

20 (2) "Harnosal" means a compound of sulfamethizole and
21 sulfaethidole. A 500-milligram tablet contains 350
22 milligrams of sulfamethizole and 150 milligrams of
23 sulfaethidole.

24 (3) "Phosetamin" means a compound of potassium salt of
25 the monoester (2-ethylamine) of phosphoric acid, magnesium

1 salt of the monoester (2-ethylamine) of phosphoric acid, and
2 calcium salt of the monoester (2-ethylamine) of phosphoric
3 acid. A 350-milligram tablet contains 145.8 milligrams of
4 the potassium salt, 145.8 milligrams of the magnesium salt,
5 and 58.4 milligrams of the calcium salt SALT.

6 Section 3. Authorization of medication. The
7 manufacture, sale, possession, and distribution of
8 calcium-EAP, harnosal, and phosetamin TO PROVIDE FOR THE
9 CONTINUATION OF MEDICATION INITIATED BY A PHYSICIAN FOR
10 MULTIPLE SCLEROSIS are lawful within this state.

11 Section 4. Health care facility may not interfere. A
12 health care facility may not interfere with the
13 physician-patient relationship by restricting or forbidding
14 the use of calcium-EAP, harnosal, or phosetamin when
15 prescribed or administered by a physician.

16 Section 5. Health care facility immunity. No health
17 care facility or employee thereof may be held liable for the
18 administration of calcium-EAP, harnosal, or phosetamin to
19 any person.

20 Section 6. Physician not subject to disciplinary
21 action. A physician may not be disciplined by the board of
22 medical examiners for prescribing or administering
23 calcium-EAP, harnosal, or phosetamin to a patient under his
24 care in the treatment of any malignancy, disease, illness,
25 or physical condition.

1 Section 7. Medication not endorsed -- permitted as
2 dietary supplement. [This act]:

3 (1) is not an endorsement of calcium-EAP, harnosal, or
4 phosetamin for the treatment of any malignancy, disease,
5 illness, or physical condition; and

6 (2) does not prohibit use of calcium-EAP, harnosal, or
7 phosetamin as a dietary supplement.

8 Section 8. Medication not required. [This act] does
9 not require:

10 (1) a physician to prescribe calcium-EAP, harnosal, or
11 phosetamin for any patient; or

12 (2) a physician, pharmacist, pharmacy, manufacturer,
13 or distributor to manufacture, sell, or distribute
14 calcium-EAP, harnosal, or phosetamin.

15 Section 9. Effective date. This act is effective on
16 passage and approval.

-End-